Pharvaris prices $115M share offering to fund rare disease pipeline
What's the deal? Pharvaris, a Netherlands-based biotech company listed on Nasdaq, has priced an underwritten public offering of roughly 3.9 million ordinary shares at $29.68 each. The deal is expected to bring in approximately $115M in gross proceeds before underwriting discounts, commissions, and expenses.
The offering is led by Morgan Stanley, Leerink, Cantor, and Wells Fargo. Underwriters also have a 30-day option to purchase an additional 581,199 shares at the offering price. The deal is expected to close on or about May 11, 2026.
Why now? Pharvaris is trading near its 52-week high of $31.14, making this an opportune window to raise capital at a favourable price. The company's market cap sits at roughly $1.9B, and the stock gained 1.38% on the day of the announcement — with a peak intraday move of 9.4%.
What could go wrong? The offering dilutes existing shareholders, with nearly 3.9 million new shares entering the market — and potentially more if the underwriters exercise their full option. Net proceeds will also be reduced by fees and expenses. Closing remains subject to customary conditions and is not guaranteed.
The signal: Biotech companies frequently tap public markets when their stock is near highs, locking in capital to fund clinical programmes and operations. For Pharvaris, which focuses on treatments for hereditary angioedema, this raise signals confidence in its pipeline and a willingness from institutional investors to back the company's next phase of development.
Read more: stocktitan.net
